IL248095A0 - יחידת מינון המכילה אמטריסיטאבין, טנופוויר, דרונאויר וריטונאויר - Google Patents

יחידת מינון המכילה אמטריסיטאבין, טנופוויר, דרונאויר וריטונאויר

Info

Publication number
IL248095A0
IL248095A0 IL248095A IL24809516A IL248095A0 IL 248095 A0 IL248095 A0 IL 248095A0 IL 248095 A IL248095 A IL 248095A IL 24809516 A IL24809516 A IL 24809516A IL 248095 A0 IL248095 A0 IL 248095A0
Authority
IL
Israel
Prior art keywords
darunavir
emtricitabine
tenofovir
ritonavir
dosage form
Prior art date
Application number
IL248095A
Other languages
English (en)
Inventor
Hrakovsky Julia
Haronsky Elina
Nitzan Shahar
Original Assignee
Teva Pharma
Hrakovsky Julia
Haronsky Elina
Nitzan Shahar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Hrakovsky Julia, Haronsky Elina, Nitzan Shahar filed Critical Teva Pharma
Publication of IL248095A0 publication Critical patent/IL248095A0/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL248095A 2014-04-08 2016-09-27 יחידת מינון המכילה אמטריסיטאבין, טנופוויר, דרונאויר וריטונאויר IL248095A0 (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461976917P 2014-04-08 2014-04-08
US201562119520P 2015-02-23 2015-02-23
PCT/IB2015/052493 WO2015155673A1 (en) 2014-04-08 2015-04-07 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir

Publications (1)

Publication Number Publication Date
IL248095A0 true IL248095A0 (he) 2016-11-30

Family

ID=53264692

Family Applications (1)

Application Number Title Priority Date Filing Date
IL248095A IL248095A0 (he) 2014-04-08 2016-09-27 יחידת מינון המכילה אמטריסיטאבין, טנופוויר, דרונאויר וריטונאויר

Country Status (6)

Country Link
EP (1) EP3129009A1 (he)
AU (1) AU2015245217A1 (he)
CA (1) CA2942877A1 (he)
IL (1) IL248095A0 (he)
TW (1) TW201622731A (he)
WO (1) WO2015155673A1 (he)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
KR101820084B1 (ko) * 2016-03-31 2018-01-18 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
KR101777564B1 (ko) 2016-05-30 2017-09-12 영남대학교 산학협력단 테노포비어 디소프록실 유리염기를 함유한 정제 조성물 및 이의 제조방법
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CA3058162A1 (en) * 2017-03-30 2018-10-04 Boston Biomedical, Inc. Compositions for treating and/or preventing cancer
CN108727401A (zh) * 2017-04-20 2018-11-02 盐城迪赛诺制药有限公司 达鲁那韦新晶型及其制备方法和应用
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CN111407736A (zh) * 2020-03-30 2020-07-14 苏州弘森药业股份有限公司 一种富马酸替诺福韦二吡呋酯片的制备工艺

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
KR100336699B1 (ko) 1992-08-25 2002-05-13 윌리암스 로저 에이 레트로바이러스 프로테아제 저해제로서 유용한히드록시에틸아미노 술폰아미드
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
MY145265A (en) 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
AU2004206827A1 (en) 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
DE602005009366D1 (de) * 2004-07-08 2008-10-09 Tibotec Pharm Ltd Kombination aus tenofovir, ritonavir und tmc114
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CA2687647A1 (en) * 2007-05-22 2008-11-27 Ultimorphix Technologies B.V. Tenofovir disoproxil hemi-fumaric acid co-crystal
PA8809601A1 (es) 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
CA2744211A1 (en) * 2008-11-21 2010-05-27 Ultimorphix Technologies B.V. Wet granulation of tenofovir, emtricitabine and efavirenz
EP2332532A1 (fr) * 2009-11-20 2011-06-15 Assistance Publique, Hopitaux De Paris Nouveaux schémas d'administration de multithérapies utiles pour le traitement des personnes atteintes du virus de l'immunodéficience humaine (vih)
EP2332544A1 (fr) 2009-11-20 2011-06-15 Assistance Publique, Hopitaux De Paris Nouvelle composition pharmaceutique utile pour le traitement des personnes atteintes du virus de l'immunodéficience humaine (VIH)
ES2598823T3 (es) 2011-07-07 2017-01-30 Janssen R&D Ireland Formulaciones de darunavir
WO2013057469A1 (en) 2011-10-20 2013-04-25 Cipla Limited Pharmaceutical antiretroviral compositions
GB201119032D0 (en) * 2011-11-03 2011-12-14 Isis Innovation Multisomes: encapsulated droplet networks
EA026138B1 (ru) * 2012-02-03 2017-03-31 Джилид Сайэнс, Инк. Комбинированная терапия, включающая тенофовир алафенамида гемифумарат и кобицистат, для применения для лечения вирусных инфекций
US20140163096A1 (en) * 2012-12-07 2014-06-12 Pam Golden Methods and compositions for treating hiv-associated diarrhea
IN2013MU01749A (he) 2013-05-15 2015-06-26 Cipla Ltd
CA2918707A1 (en) * 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir

Also Published As

Publication number Publication date
AU2015245217A1 (en) 2016-10-13
CA2942877A1 (en) 2015-10-15
TW201622731A (zh) 2016-07-01
EP3129009A1 (en) 2017-02-15
WO2015155673A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
HK1249103B (zh) 多環氨甲醯基吡啶酮化合物及其藥物用途
HK1248547A1 (zh) 包含替諾福韋和恩曲他濱的藥物製劑
EP3302442A4 (en) PHARMACEUTICAL FORM AND USE THEREOF
IL248095A0 (he) יחידת מינון המכילה אמטריסיטאבין, טנופוויר, דרונאויר וריטונאויר
IL252397A0 (he) תכשירים רוקחיים, הכנה ושימושים בהם
IL290114A (he) תכשירים רוקחיים, הכנה ושימושים בהם
HK1220390A1 (zh) 包括恩曲他濱，替諾福韋，達蘆那韋和利托那韋的單位劑型以及包含達蘆那韋和利托那韋的單體片劑
LT3229843T (lt) Farmacinė kompozicija, jos paruošimo būdas ir naudojimas
HK1223630A1 (zh) 抗- 療法的實施與用量
HRP20181406T1 (hr) Farmaceutski dozni oblici
HRP20182167T1 (hr) Derivati benzilhidroksida, njihova priprava i njihova terapeutska uporaba
PT3023093T (pt) Preparação medicinal à base de diosmectite